Screener
ArriVent BioPharma, Inc. AVBP Business Segments — Segment Reporting Other Item Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| (in thousands) | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Other Firmonertinib costs | 3,883 | 2,262 |
| Total Firmonertinib | 15,083 | 14,304 |
| Research and development: Early-stage programs | 12,307 | 40,981 |
| Research and development: Personnel-related and other internal costs | 10,227 | 6,005 |
| General and administrative: Personnel-related costs | 6,183 | 3,331 |
| General and administrative: Other costs | 2,311 | 2,151 |
| Other segment items (a) | (2,791) | (2,385) |
| Net loss | $43,320 | $64,387 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount?
- ArriVent BioPharma, Inc. (AVBP) reported business segments — segment reporting other item amount of -$2.79M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount changed year-over-year?
- ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount decreased by 17.0% year-over-year, from -$2.39M to -$2.79M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount has grown at a 46.1% compound annual growth rate (CAGR), from -$5.26M to -$11.23M.
- What does business segments — segment reporting other item amount mean?
- This metric represents miscellaneous financial adjustments or non-recurring items specific to the business segment that do not fall under standard operating expense categories. It provides transparency into unique accounting impacts or one-time events that affect the segment's reported financial performance. Analysts monitor this to identify non-operational volatility in the segment's bottom line.
Ask your AI about ArriVent BioPharma, Inc.'s business segments — segment reporting other item amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude